Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Business Of Biotech cover art

Business Of Biotech

Business Of Biotech

Written by: Ben Comer
Listen for free

About this listen

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

© 2026 Business Of Biotech
Biological Sciences Economics Management Management & Leadership Science
Episodes
  • Preparing For Commercial Launch In Oncology With Candel Therapeutics' Paul Peter Tak, M.D., Ph.D.
    Nov 16 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA's Fast Track and RMAT designations aided communication and CMC planning, and how an outsourced commercial model can help companies prepare for launch and avoid premature fixed costs.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    56 mins
  • Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
    Nov 9 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matter as much as the molecule itself. He also discusses partnering in China, and the potential for psychedelics in treating psychiatric disorders, including bretisilocin, AbbVie's first psychedelic clinical program.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    50 mins
  • Translating A New Discovery Into A Novel Cancer Therapy With Grid Therapeutics' Ned Patz, M.D.
    Nov 2 2026

    We love to hear from our listeners. Send us a message.

    On this week's episode of the Business of Biotech, Edward (Ned) Patz, M.D., Cofounder and CEO at Grid Therapeutics, explains how a Duke University lab discovery turned into Grid Therapeutics and two clinical-stage cancer immunotherapy programs. Ned talks about discovering the human-derived antibody treatment GT103 and novel Compliment Factor H (CFH) target, the messy realities of funding a new therapeutic approach in cancer, and the leadership lessons that come with running a scrappy virtual biotech.

    Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

    Subscribe to our monthly Business of Biotech newsletter.

    Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

    Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/


    Show More Show Less
    54 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet